NDC 55513-190

Neulasta

Pegfilgrastim

Neulasta is a Subcutaneous Injection in the Human Prescription Drug category. It is labeled and distributed by Amgen Inc. The primary component is Pegfilgrastim.

Product ID55513-190_1ca38d81-c6b9-4a90-97d3-35089b4aba67
NDC55513-190
Product TypeHuman Prescription Drug
Proprietary NameNeulasta
Generic NamePegfilgrastim
Dosage FormInjection
Route of AdministrationSUBCUTANEOUS
Marketing Start Date2002-04-01
Marketing CategoryBLA / BLA
Application NumberBLA125031
Labeler NameAmgen Inc
Substance NamePEGFILGRASTIM
Active Ingredient Strength6 mg/.6mL
Pharm ClassesGranulocyte Colony-Stimulating Factor [CS],Granulocyte-Macrophage Colony-Stimulating Factor [CS],Increased Myeloid Cell Production [PE],Leukocyte Growth Factor [EPC]
NDC Exclude FlagN
Listing Certified Through2020-12-31

Packaging

NDC 55513-190-01

1 SYRINGE in 1 CARTON (55513-190-01) > .6 mL in 1 SYRINGE
Marketing Start Date2002-04-01
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 55513-190-01 [55513019001]

Neulasta INJECTION
Marketing CategoryBLA
Application NumberBLA125031
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitML
Marketing Start Date2002-04-01

Drug Details

Pharmacological Class

  • Granulocyte Colony-Stimulating Factor [CS]
  • Granulocyte-Macrophage Colony-Stimulating Factor [CS]
  • Increased Myeloid Cell Production [PE]
  • Leukocyte Growth Factor [EPC]

Medicade Reported Pricing

55513019001 NEULASTA 6 MG/0.6 ML SYRINGE

Pricing Unit: ML | Drug Type:

NDC Crossover Matching brand name "Neulasta" or generic name "Pegfilgrastim"

NDCBrand NameGeneric Name
55513-190Neulastapegfilgrastim
55513-192Neulastapegfilgrastim
67457-833Fulphilapegfilgrastim
70121-1627FYLNETRApegfilgrastim

Trademark Results [Neulasta]

Mark Image

Registration | Serial
Company
Trademark
Application Date
NEULASTA
NEULASTA
78103592 2748844 Live/Registered
Amgen Inc.
2002-01-18

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.